Drugs / MRKAd5 HIV-1 gag vaccine
MRKAd5 HIV-1 gag vaccine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00857311 | May 2004 → Jan 2006 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00849680 | Apr 2003 → Mar 2005 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT00080106 | Jun 2004 → Sep 2007 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRK Ad5 HIV-1 gag vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00080106 ↗ |
| Known as | MRKAd 5 HIV-1 gag Monovalent vaccine | “some participants will be randomized to an MRKAd 5 HIV-1 gag Monovalent vaccine” NCT00849680 ↗ |
| Known as | V520 | “MRKAd5 HIV-1 gag vaccine (V520)” NCT00857311 ↗ |
| Modality | Vaccine | “The MRK Ad5 HIV-1 gag vaccine uses a replication-defective adenovirus vector” NCT00080106 ↗ |
| Route | Intramuscular | “Both vaccine and placebo will be injected into the upper arm muscle.” NCT00080106 ↗ |